At Corvidia, we create precision therapies

We are building a pioneering company to introduce medicines which alter the natural history of Cardio-Renal diseases.

Mission

At Corvidia, we harness the power of intersections.

This is our guiding philosophy, as we examine the genomics of living networks, deploy strategies for value-based drug development, and come together as individuals and partners with diverse expertise to form teams of unique abilities. We find connections no one has made, to find treatments no one has found, in the service of our patients, for whom relief from disease is our fuel. This is our engine – the pursuit of precision Cardio-Renal medicines – their discovery, development, and ultimate delivery to our patients.

History

Corvidia was founded based on the discovery of genomic determinants of inflammatory risk in cardiac and renal patients. 

Seeded by Sofinnova Partners in 2015, Corvidia raised $26 Million in an A Series financing round from Sofinnova Partners and Apple Tree Partners.  MedImmune, the global biologics Research and Development arm of AstraZeneca, joined the Board of Directors. In 2018, Sofinnova Partners, Apple Tree and MedImmune were joined by a syndicate of new investors. Venrock led the $60M Series B financing and was joined by five additional new investors: Andera (formerly Edmond de Rothschild), Cormorant Asset Management, HBM Healthcare Investments, Fresenius Medical Care Ventures GmbH and Venrock Healthcare Capital Partners (VHCP)

FOUNDERS

EXECUTIVE

CLINICAL / STRATEGY

FINANCE

R&D

CMC

Marc De Garidel

Chief Executive Officer

Bio +

Marc de Garidel is the Chief Executive Officer of Corvidia Therapeutics. Prior to joining Corvidia, Marc was the Chairman and Chief Executive Officer of Ipsen SA between 2010 and 2016 where he led the company through a significant transformation and spearheaded growth of operations in the United States. Prior to his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products. He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is currently the president of G5 Sante’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG as a member and in 2018 as Vice Chair. He remains Chair of the Board of Directors for Ipsen SA. Marc holds a Master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris and an executive MBA from Harvard Business School.

Michael Davidson

Chief Scientific Officer

Bio +

Michael Davidson is a founder and serves as the Chief Scientific Officer of Corvidia Therapeutics. Michael is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years. Michael was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008 that was acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Michael is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association (2010-2011). Michael received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.

Rahul Kakkar

Chief Medical Officer & Chief Strategy Officer

Bio +

Rahul Kakkar is a founder and leads clinical and strategic development at Corvidia. Previously, Rahul was Director for Emerging Innovations at AstraZeneca, responsible for re-profiling assets across preclinical and clinical development. Through out-licensing efforts, his programs enabled the raise of over $85M in venture-backed capital. Rahul served as a consultant to Venrock and Novartis Venture Funds. Rahul is dual-trained as a physician-scientist via the American Board of Internal Medicine Fast Track program. His basic research at the Brigham and Women’s Hospital in Boston focused on immune signaling and novel biomarkers in cardiac ventricular maladaptation. He trained in Clinical Cardiology at the Massachusetts General Hospital. Rahul received his BA and MD from Tufts University where he graduated as a junior-inductee of the Alpha Omega Alpha honor society and served as an Albert Schweitzer Fellow.

Matt Devalaraja

Executive Vice President, Head of Research & Development

Bio +

Matt Devalaraja is a founder and is the Head of R&D of Corvidia. Matt is an immunologist with over 19 years of experience in drug discovery and development across multiple therapeutic areas. Matt was Director of Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for Corvidia. Prior to that he was Head of Immunology Research, Pharmacokinetics and Toxicology groups at Human Genome Sciences and was integral to the approval of Benlysta for Lupus and Raxibacumab for Anthrax. He started his career at Pfizer Ann Arbor and brought forth the first biologic program for Pfizer’s Global Immunology portfolio. As Head of Biologics Discovery at Pfizer Ann Arbor, he initiated multiple programs across various therapeutic areas including immunology and cardiovascular space, many of which are currently in various stages of clinical development. He is currently on the board of P2D Biosciences and is a founder of multiple startup biotech companies. Matt received his PhD from University of Kentucky and Post Doctoral training at Vanderbilt University.

Ram Aiyar

Executive Vice President, Head of Business Development

Bio +

Ram Aiyar is a founder at Corvidia where he serves as Executive Vice President and Head of Business development. In this role, he leads the finance, transactions, and operations activities. Prior to Corvidia, Ram was an Entrepreneur-in- Residence at BioHealth Innovation (BHI), and worked to successfully establish and shape early stage biotech startups in the Maryland region. He operated as interim-management with the scientific founders in order to support product development and corporate development strategies. Ram has built multiple strategic alliances and partnerships with stakeholders from biopharma and academic communities. He brings over 15 years of diverse expertize with product development experience at Janssen Pharmaceuticals, finance experience at JP Morgan, and investment experience at Sofinnova Partners. Ram was the recipient of the Philip B. Hoffmann award for excellence in Science at Janssen for work done on erythropoietin agonists. He holds a MS/PhD from Drexel University and an MBA from INSEAD.

Douglas Kling

Sr. VP Clinical Operations

Bio +

Douglas joined Corvidia in December 2017 and leads clinical operations. During his 22-year career in clinical development Douglas has managed clinical activities for a number of successful products including Humira®, Lovaza®, Kengreal® and Epanova®. Before joining Corvidia Douglas was Sr. Vice President of Clinical Development and Project management at Matinas BioPharma Holdings, Inc. where he built a clinical development team and managed development activities. Prior to working at Matinas, Douglas was the Sr. VP of Clinical Development at Omthera, where he directed the clinical program for Epanova® which lead to NDA approval. Douglas has a BS in biological sciences from Duke University and an MBA from Rutgers Business School.

GaoZhong Zhu

VP, Head of Pharmaceutical Development and Manufacturing

Bio +

Gaozhong Zhu is VP, Head of Pharmaceutical Development and Manufacturing at Corvidia. He is responsible for drug product and drug substance characterization, formulations and life cycle management of the drug product. Prior to joining Corvidia, Gaozhong was Senior Director in Process Development & Technical Services at Shire, primarily responsible for drug product formulation and process development, tech transfer for drug product manufacturing and process validation, as well as providing technical services for commercial product manufacturing and due diligence & integration of externally acquired products. Over the 15 years at Shire, Gaozhong has contributed to commercialization ofseveral biologics. Prior to Shire, Gaozhong worked as a lead scientist at Biogen, responsible for pharmaceutical development of protein therapeutics.

Mark Melville

Sr. Dir Process Development

Bio +

Mark Melville is the Senior Director of CMC and manages the outsourcing of all development and manufacturing activities for drug substance at Corvidia. Mark previously managed drug substance development and manufacture of a pipeline of biosimilar products at Epirus Biopharmaceuticals, bringing multiple products to the clinical stage. He has been in the in biotherapeutic development and manufacturing for over 16 years with positions at Wyeth Biopharma, Pfizer, and Percivia. Mark received his PhD from the University of Washington.

Larry Lo

Sr. Dr. R&D

Bio +

Larry Lo currently is a Senior Director of R&D at Corvidia. Larry was Director of Global Biomarker Discovery and Development at Biogen, responsible for overseeing bioanalytical and biomarker assays, including development, validation/qualification and data review in nonclinical/clinical studies for neurodegenerative and fibrotic diseases at multiple stages, from phase I to post-approval studies. During his career at Human Genome Sciences and MedImmune, he was a central member for discovery and development of therapeutic antibody in autoimmune, infectious and oncology diseases. Larry received his Ph.D. from The Scripps Research Institute where his research work focused on pioneer work to discovery catalytic antibody using in vitro phage display system.

Nicholas Coscia

Controller

Bio +

Nick has been with Corvidia since August of 2018, he is responsible for Corvidia’s accounting and financial reporting function, as well as its tax, treasury, and financial planning and analysis functions. Nick has been with Corvidia since August of 2018, he has more than 25 years of experience in managing the financial function of companies in multiple industries. Nick received his B.S. in Accounting from Suffolk University and his MBA from New Hampshire College.

Kurt Herzog

Senior Business Associate

Bio +

Kurt Herzog is a Senior Business Associate at Corvidia and leads health economics research while supporting corporate strategy and fundraising, finance, and clinical data analysis. Kurt was formerly a senior analyst at BioHealth Innovation where he worked directly with startup founders to commercialize early-stage biotech and healthtech research from Johns Hopkins, the NIH, and UMD. His prior experience includes investment banking, project finance, and international micro-finance. He received his BA from Bowdoin College in Economics and Environmental Studies with a concentration in Natural Science.

Dianne Noones

Executive Assistant

Board of Directors

Aaron Kantoff – Apple Tree Partners

Bio +

Aaron Kantoff, Principal, has significant early and late-stage biotech experience, as well as a background in financial analysis and restructuring. Since joining ATP in 2011, he has been instrumental in helping to create the current investment strategy for the therapeutics team, and has been involved with investing in and building many of the portfolio companies.Prior to joining ATP in 2011, Aaron was a partner at Recess Global, LLC, an investment company, focused on funding startups. Prior to starting Recess, Aaron was a member of the investment banking team at Rothschild Inc., in the Restructuring Group. Selected transactions that he worked on at Rothschild Inc. include: advising the U.S Treasury on restructuring of Chrysler Group, LLC; assisting Milacron Inc. with the Section 363 sale of assets; working with Delphi Automotive on its in-court Chapter 11 bankruptcy; developing the Penton Media “Pre-packaged” Chapter 11 filing. In addition to his role with Apple Tree, Aaron served as Executive Director of Business Development & Corporate Strategy of Braeburn Pharmaceuticals from 2012 to 2014. Aaron holds a Bachelor of Science in Finance and International Business from the New York University Stern School of Business.

Graziano Seghezzi – Sofinnova Partners

Bio +

Graziano Seghezzi is a Partner at Sofinnova Partners which he joined in 2006. He seeded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seeded and is on the Board of MISSION Therapeutics (United Kingdom), Crescendo Biologics (United Kingdom) and Hookipa Biotech (Austria). He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003. Prior to that, Graziano spent five years working in academic research at New York University’s School of Medicine, studying oncology and cardiovascular diseases. Graziano holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands).

Karim Helmy – Venrock

Bio +

Karim Helmy joined Venrock as a vice president in 2017 and focuses on healthcare investments across sectors and stages. Prior to joining Venrock, Karim was an Engagement Manager in the healthcare practice at McKinsey & Company where he worked with biopharma and device companies of all sizes focusing on clinical, regulatory and BD strategy. Earlier in his career, Karim worked at Genentech where he led a research effort that identified a novel immune receptor and advanced a molecule based on this discovery into pre-clinical development. Karim trained as a physician-scientist, earning MD/PhD degrees from New Jersey Medical School, where he where he graduated with Alpha Omega Alpha honors and received the Stanley S. Bergen, Jr. Medal of Excellence, awarded to the top graduating student in the class. He completed thesis research as a Howard Hughes Medical Institute Fellow at Memorial Sloan-Kettering Cancer Center studying gene regulation in primary brain tumors. He went on to complete an internship in Internal Medicine at Columbia University Medical Center. Karim received an undergraduate degree in Biological Sciences from Stanford University.

Marc De Garidel - Corvidia

Bio +

Marc de Garidel is the Chief Executive Officer of Corvidia Therapeutics. Prior to joining Corvidia, Marc was the Chairman and Chief Executive Officer of Ipsen SA between 2010 and 2016 where he led the company through a significant transformation and spearheaded growth of operations in the United States. Prior to his experience at Ipsen SA, Marc spent 15 years with the multinational biopharmaceutical company Amgen. Based primarily in Europe, Marc helped Amgen establish and build a significant business in nephrology and oncology, achieving leadership positions for several portfolio products. He began his career with Eli Lilly and Company where he worked in the United States, France and Germany. In Europe, Marc has played a prominent role in not-for-profit organizations such as the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is currently the president of G5 Sante’. Marc served on the Board of Directors for Vifor Pharmaceuticals AG as a member and in 2018 as Vice Chair. He remains Chair of the Board of Directors for Ipsen SA. Marc holds a Master’s degree in civil engineering from École Spéciale des Travaux Publics in Paris and an executive MBA from Harvard Business School.

Sylvie Gregoire – Chair

Bio +

Sylvie Grégoire, has over 25 years of international experience in the biotech and pharmaceutical industries. Sylvie was President of Shire Human Genetic Therapies (HGT), a business unit of Shire plc that focuses on Rare Diseases. Under her leadership, the business unit grew from $300M to $1.5B. Prior to joining Shire HGT, Sylvie was Executive Chairwoman of IDM Pharma. She was previously CEO of GlycoFi, a privately held protein technology company, held executive positions at Biogen Inc., and worked at Merck & Co. in the US and abroad. Sylvie is also a non-executive member of the board of 3 public companies: Galenica, a Swiss pharmaceutical company, NovoNordisk a Danish pharmaceutical company and PerkinElmer an instrumentation and diagnostics company. She has a depth of experience in the management of commercial operations, manufacturing and regulatory affairs. Sylvie holds a Bachelor of Science degree from Laval University and a Doctoral degree from the State University of New York at Buffalo.

Tyrell Rivers – Medimmune

Bio +

Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s corporate development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing and, at Merck & Company, Inc. where he led the technical support for multiple commercial vaccine franchises, subsequently directing global business initiatives for accessing key technologies in research and development. Dr. Rivers earned his Bachelor of Science degree in chemical engineering from the Massachusetts Institute of Technology and his PhD in chemical engineering from University of Texas at Austin. He earned his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for G1 Therapeutics (GTHX), Viela Bio and Armaron Bio Ltd. He is a board observer for several private companies.